Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

Cited In for PubMed (Select 10882612)


Comparative evaluation of recombinant protein production in different biofactories: the green perspective.

Merlin M, Gecchele E, Capaldi S, Pezzotti M, Avesani L.

Biomed Res Int. 2014;2014:136419. doi: 10.1155/2014/136419. Epub 2014 Mar 12. Review.


The state of norovirus vaccines.

Debbink K, Lindesmith LC, Baric RS.

Clin Infect Dis. 2014 Jun;58(12):1746-52. doi: 10.1093/cid/ciu120. Epub 2014 Feb 27.


Proteomics: a biotechnology tool for crop improvement.

Eldakak M, Milad SI, Nawar AI, Rohila JS.

Front Plant Sci. 2013 Feb 28;4:35. doi: 10.3389/fpls.2013.00035. eCollection 2013.


Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans.

Both L, van Dolleweerd C, Wright E, Banyard AC, Bulmer-Thomas B, Selden D, Altmann F, Fooks AR, Ma JK.

FASEB J. 2013 May;27(5):2055-65. doi: 10.1096/fj.12-219964. Epub 2013 Jan 31.


Plant-derived virus-like particles as vaccines.

Chen Q, Lai H.

Hum Vaccin Immunother. 2013 Jan;9(1):26-49. doi: 10.4161/hv.22218. Epub 2012 Sep 20. Review.


Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.

Tan M, Jiang X.

Nanomedicine (Lond). 2012 Jun;7(6):889-97. doi: 10.2217/nnm.12.62. Review.


Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.

Velasquez LS, Shira S, Berta AN, Kilbourne J, Medi BM, Tizard I, Ni Y, Arntzen CJ, Herbst-Kralovetz MM.

Vaccine. 2011 Jul 18;29(32):5221-31. doi: 10.1016/j.vaccine.2011.05.027. Epub 2011 Jun 2.


Model systems for the study of human norovirus Biology.

Vashist S, Bailey D, Putics A, Goodfellow I.

Future Virol. 2009 Jul;4(4):353-367.


Immunology of gut mucosal vaccines.

Pasetti MF, Simon JK, Sztein MB, Levine MM.

Immunol Rev. 2011 Jan;239(1):125-48. doi: 10.1111/j.1600-065X.2010.00970.x. Review.


Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, Ferreira J, Chen WH, Sublett R, Richardson C, Bargatze RF, Sztein MB, Tacket CO.

J Infect Dis. 2010 Dec 1;202(11):1649-58. doi: 10.1086/657087. Epub 2010 Oct 27. Erratum in: J Infect Dis. 2011 Apr 1;203(7):1036.


Noroviruses: The leading cause of gastroenteritis worldwide.

Koo HL, Ajami N, Atmar RL, DuPont HL.

Discov Med. 2010 Jul;10(50):61-70. Review.


Norwalk virus-like particles as vaccines.

Herbst-Kralovetz M, Mason HS, Chen Q.

Expert Rev Vaccines. 2010 Mar;9(3):299-307. doi: 10.1586/erv.09.163. Review.


Plant-made vaccine antigens and biopharmaceuticals.

Daniell H, Singh ND, Mason H, Streatfield SJ.

Trends Plant Sci. 2009 Dec;14(12):669-79. doi: 10.1016/j.tplants.2009.09.009. Epub 2009 Oct 14. Review.


A DNA replicon system for rapid high-level production of virus-like particles in plants.

Huang Z, Chen Q, Hjelm B, Arntzen C, Mason H.

Biotechnol Bioeng. 2009 Jul 1;103(4):706-14. doi: 10.1002/bit.22299.


Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS.

J Virol. 2009 Apr;83(7):3212-27. doi: 10.1128/JVI.01650-08. Epub 2009 Jan 28.


Plant-based vaccines against diarrheal diseases.

Tacket CO.

Trans Am Clin Climatol Assoc. 2007;118:79-87.


Genetically modified plants and human health.

Key S, Ma JK, Drake PM.

J R Soc Med. 2008 Jun;101(6):290-8. doi: 10.1258/jrsm.2008.070372. Review.


An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles.

Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, Arntzen CJ, Chen Q, Mason HS.

Vaccine. 2008 Mar 28;26(15):1846-54. doi: 10.1016/j.vaccine.2008.01.053. Epub 2008 Feb 15.


Oral vaccines: A spoonful of antigen.

Tonks A.

BMJ. 2007 Jul 28;335(7612):180-2. Review. No abstract available.


Low-dose exposure and immunogenicity of transgenic maize expressing the Escherichia coli heat-labile toxin B subunit.

Beyer AJ, Wang K, Umble AN, Wolt JD, Cunnick JE.

Environ Health Perspect. 2007 Mar;115(3):354-60. Epub 2006 Dec 19.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk